4.7 Article

Phloretin as a Potent Natural TLR2/1 Inhibitor Suppresses TLR2-Induced Inflammation

Journal

NUTRIENTS
Volume 10, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/nu10070868

Keywords

phloretin; dietary flavonoid; inflammation; TLR2; TLR1; inhibitor

Funding

  1. Konkuk University 2015

Ask authors/readers for more resources

Toll-like receptor 2 (TLR2) responses are involved in various inflammatory immune disorders. Phloretin is a naturally occurring dietary flavonoid that is abundant in fruit. Here, we investigated whether the anti-inflammatory activity of phloretin is mediated through TLR2 pathways, and whether phloretin acts as an inhibitor of TLR2/1 heterodimerization using the TLR2/1 agonist Pam(3)CSK(4). We tested the effects of phloretin on tumor necrosis factor (TNF)-alpha production induced by various TLRs using known TLR-specific agonists. Phloretin significantly inhibited Pam(3)CSK(4)-induced TRL2/1 signaling in Raw264.7 cells compared to TLR signaling induced by the other agonists tested. Therefore, we further tested the effects of phloretin in human embryonic kidney (HEK) 293-hTLR2 cells induced by Pam(3)CSK(4), and confirmed that phloretin has comparable inhibition of TLR2/1 heterodimerization to that induced by the known TLR2 inhibitor CU-CPT22. Moreover, phloretin reduced the secretion of the inflammatory cytokines TNF-alpha and interleukin (IL)-8 in Pam(3)CSK(4)-induced HEK293-hTLR2 cells, whereas it did not significantly reduce these cytokines under Pam(2)CSK(4)-induced activation. Western blot results showed that phloretin significantly suppressed Pam(3)CSK(4)-induced TLR2 and NF-kappa B p65 expression. The molecular interactions between phloretin and TLR2 were investigated using bio-layer interferometry and in silico docking. Phloretin bound to TLR2 with micromolar binding affinity, and we proposed a binding model of phloretin at the TLR2-TLR1 interface. Overall, we confirmed that phloretin inhibits the heterodimerization of TLR2/1, highlighting TLR2 signaling as a therapeutic target for treating TLR2-mediated inflammatory immune diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available